Biotechnology Analysts discuss Crinetics Pharmaceuticals’ Paltusotine Data for treatment of Carcinoid Syndrome on an Analyst/Industry conference call to be held on October 19.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- Piper Sandler biotech analysts to hold an analyst/industry conference call
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
- Crinetics 11.44M share Secondary priced at $30.59
- Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock